Ranbaxy Laboratories has been notified by the US Food and Drug Administration (USFDA) that the company is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug products. The Toansa facility is now subject to certain terms of a consent decree of permanent injunction entered against Ranbaxy in January 2012.For more information call- 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment